Important NeuMoDx Update

After careful consideration, we have decided to discontinue the development and further commercialization of the NeuMoDx 96 and 288 Molecular Systems.

This decision comes after a thorough review process on the options for the future of these integrated clinical testing platforms. In light of the post-pandemic market developments for these types of systems, the NeuMoDx systems are no longer aligned with our strategic goals.

We understand this decision will likely create inconveniences for our valued customers.

We will continue to provide support to our NeuMoDx customers, including ongoing maintenance, technical support, warranty services and the provision of necessary consumables.